Computational Systems Medicine and Metabolomics Junior Research Groups

Starting in Summer 2022, Jun.-Prof. Elisa Araldi and Jun.-Prof. Thierry Schmidlin joined the DIASyM research core and started their junior research groups in Computational Systems Medicine and Metabolomics. With their expertise they will complement the DIASyM research core: They will facilitate the depth analyses and integration of complex data sets including proteome, lipidome, metabolome, transcriptome, genetics and deep clinical phenotyping to unravel the molecular architecture of the heart failure (HF) syndrome.

Read article

Status Meeting 2022

@ TUM Akademiezentrum Raitenhaslach, Nov 2022

Read article

MSCoreSys status meeting 2022

The members of the MSCoreSys research initiative met on the 26th and 27th of September 2022 in Heidelberg to hold their annual status meeting. With more than 100 scientists on site, the four research cores from Berlin, Mainz, Munich and Heidelberg presented and discussed the progress of their individual projects, exchanged on the progress of the common aim of establishing a mass spectrometry based diagnostic pipeline in systems medicine and kicked off substantial networks working towards the consolidation of the MSCoreSys research initiative.

Read article

Registration for 14th European Summer School: Advanced Proteomics

Register now for the 14th European Summer School: Advanced Proteomics in Brixen.

Read article

Junior Research Group completes SMART-CARE

Dr. Junyan Lu joined SMART-CARE consortium on December 1st, 2021 to lead a new junior group of "Computational Mass-spectrometry, Multi-omics and Precision Oncology"

With his skills in biomedical data science and experience in collaborative studies, Dr. Lu leads a junior group sitting at the interface between the experimental, clinical and computational teams in SMART-CARE. The junior group aims to develop new computational methods for the robust and sensitive mining of primary mass spectrometry data, as well as the efficient integrating of mass spectrometry data with other omics and clinical data, which will serve as a solid foundation for patient stratification and biomarker discovery.

Read article